ClinConnect ClinConnect Logo
Search / Trial NCT06384183

Kerecis Real-World Fish Skin Graft Registry

Launched by KERECIS LTD. · Apr 22, 2024

Trial Information

Current as of November 05, 2025

Enrolling by invitation

Keywords

ClinConnect Summary

This is a real-world, non-interventional registry called the Kerecis Real-World Fish Skin Graft Registry (ISACOD). It looks at how well the Kerecis Fish Skin Graft device works in everyday medical practice for various wounds—like diabetic foot ulcers, pressure ulcers, venous leg ulcers, surgical wounds, and other soft-tissue wounds—over about a year. Because it’s observational, it does not assign treatments or change how care is given; instead, it collects information from patients who have already been treated with the device to understand safety and how wounds heal in real-life settings.

Who can be included? Any patient who gives informed consent, of any age or sex, and who has at least one wound treated with a Kerecis device within the month before enrollment. There are no listed exclusion criteria. The study plans to enroll about 600 people at multiple centers across the United States. Participants will have data collected during routine care for up to 12 months, focusing on whether the device causes problems or allergies, whether the wound gets infected, how long it takes to heal, and how often wounds completely close. The registry is sponsored by Kerecis Ltd., and results are not yet available.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Provided informed consent
  • Has at least one target wound treated with a Kerecis device according to physician medical judgement within one calendar month prior to the registry enrollment date
  • Exclusion Criteria:
  • None

About Kerecis Ltd.

Kerecis Ltd. is a pioneering biotechnology company focused on developing regenerative medicine solutions through the use of fish skin as a biologic alternative for wound healing and tissue regeneration. Leveraging advanced scientific research and innovative technology, Kerecis aims to address unmet medical needs in the treatment of chronic wounds, surgical wounds, and soft tissue reconstruction. The company's commitment to enhancing patient outcomes is reflected in its robust clinical trial programs, which are designed to validate the safety and efficacy of its products. By harnessing the natural properties of fish skin, Kerecis Ltd. is at the forefront of transforming wound care and improving the quality of life for patients worldwide.

Locations

Sarasota, Florida, United States

Sarasota, Florida, United States

Greensboro, North Carolina, United States

Beavercreek, Ohio, United States

Columbus, Ohio, United States

San Antonio, Texas, United States

Patients applied

0 patients applied

Trial Officials

Anne Swearingen

Principal Investigator

Kerecis Ltd.

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported